Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

24 August 2020 : Laboratory Research  

Olmutinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells

Jiansheng Zhong1ABE*, Jinli Zhang2AB, Xiaoyang Yu3BF, Xing Zhang1CD, Linping Dian1CD

DOI: 10.12659/MSM.924922

Med Sci Monit 2020; 26:e924922

Figure 5 Olmutinib potentiated the efficacy of Dox in ETS1-overexpressing leukemia cell xenograft model in vivo. (A–C) The image of tumor size excised from the mice and the euthanized mice after implantation in different groups. (D–F) The alteration of tumor volume (D), tumor diameter (E) and body weight (F) over time after K562/ADR ETS1 overexpressing cells implantation, in mice received saline, Dox, Olm or Olm+Dox, respectively. (n=3). * P<0.05, ** P<0.01 and *** P<0.001 vs. Saline; # P<0.05, ## P<0.01 and ### P<0.001 vs. Olm; & P<0.05, && P<0.01 and &&& P<0.001 vs. Dox. (G) Mean tumor weight after excising from the mice on the 30th day after implantation (n=3). ** P<0.01 vs. Saline. Dox – doxorubicin; Olm – olmutinib.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750